Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis by S. Dav&#236 et al.
ARTHRITIS & RHEUMATOLOGY
Vol. 66, No. 10, October 2014, pp 2871–2880
DOI 10.1002/art.38769
© 2014, American College of Rheumatology
Performance of Current Guidelines for Diagnosis of
Macrophage Activation Syndrome Complicating
Systemic Juvenile Idiopathic Arthritis
Sergio Davı`,1 Francesca Minoia,1 Angela Pistorio,2 AnnaCarin Horne,3 Alessandro Consolaro,2
Silvia Rosina,1 Francesca Bovis,1 Rolando Cimaz,4 Maria Luz Gamir,5 Norman T. Ilowite,6
Isabelle Kone-Paut,7 Sheila Knupp Feitosa de Oliveira,8 Deborah McCurdy,9
Clovis Artur Silva,10 Flavio Sztajnbok,11 Elena Tsitsami,12 Erbil Unsal,13 Jennifer E. Weiss,14
Nico Wulffraat,15 Mario Abinun,16 Amita Aggarwal,17 Maria Teresa Apaz,18
Itziar Astigarraga,19 Fabrizia Corona,20 Ruben Cuttica,21 Gianfranco D’Angelo,22
Eli M. Eisenstein,23 Soad Hashad,24 Loredana Lepore,25 Velma Mulaosmanovic,26
Susan Nielsen,27 Sampath Prahalad,28 Donato Rigante,29 Valda Stanevicha,30 Gary Sterba,31
Gordana Susic,32 Syuji Takei,33 Ralf Trauzeddel,34 Mabruka Zletni,24 Nicolino Ruperto,2
Alberto Martini,35 Randy Q. Cron,36 and Angelo Ravelli,35 on behalf of the
Paediatric Rheumatology International Trials Organisation, the Childhood Arthritis
and Rheumatology Research Alliance, the Pediatric Rheumatology
Collaborative Study Group, and the Histiocyte Society
Objective. To compare the capacity of the 2004
diagnostic guidelines for hemophagocytic lymphohistiocy-
tosis (HLH-2004) with the capacity of the preliminary
diagnostic guidelines for systemic juvenile idiopathic ar-
thritis (JIA)–associated macrophage activation syndrome
(MAS) to discriminate MAS complicating systemic JIA
from 2 potentially confusable conditions, represented by
active systemic JIA without MAS and systemic infection.
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Methods. International pediatric rheumatologists
and hemato-oncologists were asked to retrospectively
collect clinical information from patients with systemic
JIA–associated MAS and confusable conditions. The
ability of the guidelines to differentiate MAS from the
control diseases was evaluated by calculating the sensi-
tivity and specificity of each set of guidelines and the
kappa statistics for concordance with the physician’s
diagnosis. Owing to the fact that not all patients were
assessed for hemophagocytosis on bone marrow aspi-
rates and given the lack of data on natural killer cell
activity and soluble CD25 levels, the HLH-2004 guide-
lines were adapted to enable the diagnosis of MAS when
3 of 5 of the remaining items (3/5-adapted) or 4 of 5 of
the remaining items (4/5-adapted) were present.
Results. The study sample included 362 patients
with systemic JIA and MAS, 404 patients with active
systemic JIA without MAS, and 345 patients with sys-
temic infection. The best capacity to differentiate MAS
from systemic JIA without MAS was found when the
preliminary MAS guidelines were applied. The 3/5-
adapted HLH-2004 guidelines performed better than
the 4/5-adapted guidelines in distinguishing MAS from
active systemic JIA without MAS. The 3/5-adapted
HLH-2004 guidelines and the preliminary MAS guide-
lines with the addition of ferritin levels >500 ng/ml
discriminated best between MAS and systemic infec-
tions.
Conclusion. The preliminary MAS guidelines
showed the strongest ability to identify MAS in systemic
JIA. The addition of hyperferritinemia enhanced their
capacity to differentiate MAS from systemic infections.
The HLH-2004 guidelines are likely not appropriate for
identification of MAS in children with systemic JIA.
Macrophage activation syndrome (MAS) is a
potentially fatal complication of systemic juvenile idio-
pathic arthritis (JIA), whose pathophysiologic hallmark
is an exaggerated but ineffective immune response in-
volving excessive macrophage and T cell activation that
produces high levels of proinflammatory cytokines (1,2).
The cardinal clinical symptoms and signs of MAS are
prolonged high fever, hepatosplenomegaly, neurologic
dysfunction, and hemorrhagic manifestations. Charac-
teristic laboratory abnormalities include pancytopenia,
elevated levels of serum liver enzymes, triglycerides,
lactate dehydrogenase, and ferritin, and low levels of
fibrinogen. Although macrophage hemophagocytosis is
often seen on bone marrow examination, this finding
may be absent, particularly in the initial stages of the
syndrome (3–6). The presence of hemophagocytosis may
be governed by a relative paucity of the antiinflamma-
tory cytokine interleukin-10 (IL-10) (7).
The estimated prevalence of MAS in systemic
JIA is 10%. However, recent evidence suggests that
the syndrome may occur subclinically in an additional
30–40% of systemic JIA patients (8,9). Because MAS
bears a close similarity to the group of histiocytic
disorders belonging to hemophagocytic lymphohistiocy-
tosis (HLH), it is currently classified among the second-
ary, or acquired, forms of HLH (10,11). Along these
lines, patients with systemic JIA who develop MAS may
share similar genetic propensities as those with primary
HLH (2).
Timely diagnosis of MAS is critical to start ther-
apy before the damage related to hypercytokinemia
becomes irreversible. However, there is no single feature
that is specific for MAS, including hemophagocytosis
(12). Furthermore, MAS can be hard to distinguish from
conditions that may present with overlapping features,
such as flares of systemic JIA, sepsis or sepsis-like
syndromes, or adverse effects of antiarthritis medica-
tions. Differentiation of MAS from these conditions is
fundamental in selecting the appropriate therapeutic
interventions in a timely manner.
The difficulties in making the diagnosis empha-
size the importance of reliable criteria that could aid
physicians in identifying MAS in its earliest stages and in
distinguishing it from confusable conditions. Two sets of
guidelines are currently available for diagnosing MAS in
patients with systemic JIA. The recognition that the
syndrome is clinically similar to HLH has led some to
recommend the use of the 2004 diagnostic guidelines for
HLH (HLH-2004), which were developed primarily for
homozygous genetic disorders leading to hemophagocy-
tosis (13). An alternative approach is based on the
application of the preliminary diagnostic guidelines for
MAS complicating systemic JIA, which were created
through the analysis of a cohort of patients with MAS
compared with a group of patients with a flare of
systemic JIA (14). Although both guidelines are consid-
ered potentially suitable for detecting MAS in systemic
JIA, it has been argued that each of them is affected by
a number of potential shortcomings (2,11,15,16). How-
ever, the diagnostic performance of the 2 sets of guide-
lines has never been scrutinized using real patient data.
For this reason, the aim of the present study was to
compare the capacity of the HLH-2004 guidelines with
the capacity of the preliminary MAS guidelines to
differentiate systemic JIA–associated MAS from 2 po-
tentially confusable conditions, represented by active
systemic JIA without MAS and systemic infection.
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PATIENTS AND METHODS
Study design and patient selection. Pediatric rheuma-
tologists belonging to the Paediatric Rheumatology Inter-
national Trials Organisation, the Pediatric Rheumatology
Collaborative Study Group, and the Childhood Arthritis and
Rheumatology Research Alliance, and pediatric hemato-
oncologists belonging to the Histiocyte Society were contacted
by e-mail and invited to participate in a retrospective cohort
study of patients with systemic JIA–associated MAS and those
with 2 conditions potentially confusable with MAS, repre-
sented by active systemic JIA without evidence of MAS and
systemic infection, with data recorded in their hospital’s data-
base. To facilitate enrollment of patients with systemic infec-
tion, investigators were asked to involve infectious disease
specialists practicing at their hospital.
To be included in the study, patients with MAS had to
have been diagnosed as having systemic JIA according to the
International League of Associations for Rheumatology
(ILAR) (17) and to have had an episode of MAS diagnosed
and treated as such by the attending physician. The diagnosis
of MAS had to be based on the typical clinical and laboratory
picture of the syndrome, irrespective of evidence of macro-
phage hemophagocytosis in the bone marrow aspirate. Patients
with active systemic JIA without MAS should have also met
the ILAR criteria for systemic JIA, but should not have any
clinical or laboratory evidence of ongoing MAS. The systemic
infection sample included patients who did not have systemic
JIA and had an acute febrile infection requiring hospitaliza-
tion. Because the clinical and laboratory picture of visceral
leishmaniasis may be indistinguishable from that of MAS (18),
patients with this infection were excluded.
Investigators were asked to include in the study only
those patients seen after 2002. This time frame was chosen
because the full awareness of the typical clinical and laboratory
features of MAS was achieved in the early 2000s. Since some
patients had multiple episodes of MAS, only the first episode
had to be selected. Likewise, only one episode per patient had
to be included for both patients with active systemic JIA
without MAS and those with systemic infection.
The study protocol was approved by the Institutional
Review Board at each participating center.
Data collection procedure. Investigators who agreed to
participate in the study were asked to complete a structured
case report form with each patient’s anonymous data, and then
to enter the data into a electronic web–based database de-
veloped and handled at the coordinating center (the IRCCS
G. Gaslini of Genoa, Italy). For the purposes of the present
study, the following information was collected from both
patients with MAS and control patients: demographic data,
clinical manifestations, laboratory parameters, and histopatho-
logic features. Demographic data included sex and age at onset
of the disease. Clinical and laboratory data included those
parameters that are known to be most relevant for the
diagnosis of MAS (19). In patients with MAS, clinical and
laboratory data were collected at onset of the syndrome,
that is, at the time when the first signs or symptoms consistent
with MAS were detected. The histopathologic study investiga-
tors asked whether bone marrow aspirate or other biopsies
were performed, and for those patients in whom any of these
procedures were done, the investigators noted evidence of
macrophage hemophagocytosis.
HLH-2004 diagnostic guidelines. According to the
Histiocyte Society’s updated diagnostic and therapeutic guide-
lines for HLH (13), a diagnosis of HLH can be established
either by a molecular diagnosis with specific gene mutations
associated with HLH or by meeting 5 of 8 clinical and lab-
oratory diagnostic criteria for nonfamilial HLH. These criteria
include the following features: fever, splenomegaly, peripheral
blood cytopenias affecting at least 2 of 3 cell lineages, hyper-
triglyceridemia or hypofibrinogenemia, microscopic evidence
of hemophagocytosis in the bone marrow, spleen, or lymph
nodes, low or absent natural killer (NK) cell activity, elevated
ferritin levels, and elevated soluble CD25 (sCD25; IL-2 recep-
tor) levels. Because information about the presence of he-
mophagocytosis was not available for both control groups and
because neither NK cell activity nor sCD25 levels were deter-
mined in all patients, the diagnostic rule was modified to
enable the diagnosis of HLH when either 3 of 5 of the remain-
ing criteria (3/5-adapted) or 4 of 5 of the remaining criteria
(4/5-adapted) were met. Patients who did not meet the criteria
for cytopenia and hypertriglyceridemia/hypofibrinogenemia,
but lacked the minimum number of items necessary to assess
the respective criterion, were excluded from the analysis.
Preliminary diagnostic guidelines for MAS complicat-
ing systemic JIA. According to the preliminary MAS guide-
lines (14), the diagnosis of MAS requires the presence of 2
laboratory criteria or 2 clinical and/or laboratory criteria.
Laboratory criteria include a platelet count 262  109/liter,
aspartate aminotransferase level 59 units/liter, white blood
cell count 4.0  109/liter, and fibrinogen level 250 gm/liter.
Clinical criteria include hepatomegaly, hemorrhagic mani-
festations, and central nervous system (CNS) dysfunction.
The demonstration of macrophage hemophagocytosis on bone
marrow aspirate is requested only in doubtful cases. The
criteria were tested both in their original format and with the
additional criterion of hyperferritinemia, which was defined at
various thresholds (500, 1,000, and 2,000 ng/ml).
Statistical analysis. Quantitative data are presented as
the median with interquartile range, and categorical data are
presented as the absolute number with percentage. Compari-
son of quantitative variables between the MAS group and the
control groups was done using the Mann-Whitney U test,
whereas comparison of categorical variables was done using
the chi-square test, or Fisher’s exact test when the expected
frequency was 5.
The ability of the HLH-2004 guidelines and the pre-
liminary MAS guidelines to discriminate patients with MAS
from control patients was evaluated by calculating the sensi-
tivity of each set of guidelines (ability of the criteria to identify
a patient as having MAS who had been diagnosed as having
MAS by the attending physician) and specificity of each set of
guidelines (ability of the criteria to identify a patient as not
having MAS who had been diagnosed as having systemic JIA
without MAS or systemic infection by the attending physician).
The chance-corrected concordance between the diagnosis
yielded by the criteria and the diagnosis made by the attending
physician was assessed using Cohen’s kappa statistics (20).
According to the criteria of Landis and Koch (21), concor-
dance was defined as poor, fair, moderate, good, and almost
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perfect for the kappa values of 0.20, 0.21–0.40, 0.41–0.60,
0.61–0.80, and 0.81–1, respectively.
Receiver operating characteristic (ROC) curve analy-
ses were used to determine the cutoff value of each individual
laboratory test for the differentiation between patients with
MAS and control patients. Values that produced the most
appropriate tradeoff between sensitivity and specificity were
designated the cutoff values. For each cutoff, the sensitivity,
specificity, area under the ROC curve (AUC) (with 95%
confidence intervals [95% CIs]), and diagnostic odds ratio
(DOR) (with 95% CIs) were calculated. The DOR of a test is
the ratio of the odds of positivity in subjects with the disease to
the odds of positivity in subjects without the disease; the value
of the DOR ranges from 0 to infinity, with higher values
indicating better performance of a discriminatory test (22).
Values for laboratory biomarkers were not normalized, since
neither the HLH-2004 guidelines nor the preliminary MAS
guidelines require normalization of data.
RESULTS
The study sample included 362 patients with
systemic JIA–associated MAS, 404 patients with active
systemic JIA without MAS, and 345 patients with sys-
temic infection, who were enrolled by 95 pediatric
rheumatologists or hemato-oncologists practicing in 33
countries in 5 continents. The demographic data as well
as the frequency of clinical features in patients with
MAS and control patients are presented in Table 1. The
proportion of female patients and the age at onset of
systemic JIA were comparable between patients with
MAS and patients with systemic JIA without MAS. All
clinical manifestations were much more common in the
MAS cohort than in both control groups, with the
exception of fever, which was recorded in nearly all
patients with MAS, nearly all patients with systemic JIA
without MAS, and (as per the inclusion criterion) all
patients with systemic infection, and with the exception
of active arthritis, whose prevalence was higher in pa-
tients with systemic JIA without MAS than in patients
with MAS. The prevalence of bone marrow hemophago-
cytosis could not be compared across groups because
information about this finding was not available for
patients with systemic JIA without MAS and for those
with systemic infection.
Table 2 shows the findings from laboratory tests
in the 3 patient groups. All laboratory values were more
abnormal (showing either increased or decreased levels)
in patients with MAS when compared with control
patients, with the exception of the levels of serum
sodium, which were comparable between patients with
MAS and patients with systemic infection, and the
erythrocyte sedimentation rate (ESR), which was com-
parable between patients with MAS and patients with
systemic infection but was higher in patients with sys-
temic JIA without MAS. Overall, the values from labo-
ratory tests in patients with MAS were in line with
expectations; that is, the findings reflected the typical
changes that are known to occur in the syndrome.
The frequency of individual HLH-2004 criteria in
Table 1. Demographic, clinical, and histopathologic features of the patients with systemic JIA–associated MAS and control
patients*
Feature
Systemic JIA
with MAS
(n  362)
Systemic JIA
without MAS
(n  404)
Systemic
infection
(n  345) P† P‡
Female 208 (57.5) 203 (50.2) 172 (49.9) 0.13 0.12
Age at onset of systemic JIA,
median (IQR) years
5.3 (2.7–10.1) 5.5 (2.5–9.5) – 0.80§ –
Age at onset of systemic infection,
median (IQR) years
– – 3.8 (1.5–8.6) – –
Fever 341/355 (96.1) 382/403 (94.8) 345 (100) 0.79 0.0006
Hepatomegaly 245/350 (70) 123/400 (30.8) 39/344 (11.3) 0.0001 0.0001
Splenomegaly 201/347 (57.9) 95/399 (23.8) 23/344 (6.7) 0.0001 0.0001
Lymphadenopathy 178/346 (51.4) 115/396 (29) 29/344 (8.4) 0.0001 0.0001
Active arthritis 230/354 (65) 382/401 (95.3) 22 (6.4) 0.0001 0.0001
Central nervous system disease 122/349 (35) 7/400 (1.8) 34/344 (9.9) 0.0001 0.0001
Hemorrhagic manifestations 71/348 (20.4) 5/402 (1.2) 22/345 (6.4) 0.0001 0.0001
Bone marrow hemophagocytosis 149/249 (59.8) – – – –
* Except where indicated otherwise, values are the number of patients/total number with information available (%). IQR 
interquartile range.
† Systemic juvenile idiopathic arthritis (JIA) with macrophage activation syndrome (MAS) versus systemic JIA without MAS,
by chi-square test.
‡ Systemic JIA with MAS versus systemic infection, by chi-square test.
§ P value determined using the Mann-Whitney U test.
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each patient sample is presented in Table 3. As ex-
pected, the presence of fever did not discriminate be-
tween the patient groups, since it was recorded in nearly
all patients in each cohort. All of the other criteria were
more common in patients with MAS than in control
patients. However, the frequency of the criterion cyto-
penia in patients with MAS was very low (21.4%), owing
to the stringent threshold value of blood cell counts. For
the same reason, the criterion hypofibrinogenemia was
met in only 24.8% of MAS cases. Although a ferritin
level of 500 ng/ml was detected in 90% of patients
with MAS, it was also recorded in a sizeable percentage
(50.4%) of patients with systemic JIA without MAS.
The frequency of individual items of the prelim-
inary MAS guidelines in the 3 patient samples is pre-
sented in Table 4. The prevalence of all preliminary
MAS criteria was much greater in patients with MAS
than in each control group. Notably, in patients with
MAS, a decreased platelet count and an increased
aspartate aminotransferase level were much more fre-
quent than were hypofibrinogenemia and leukopenia.
Hepatomegaly was the most common clinical criterion
Table 2. Laboratory findings in the patients with systemic JIA–associated MAS and control patients*
Laboratory test
Systemic JIA with
MAS (n  362)
Systemic JIA without
MAS (n  404)
Systemic infection
(n  345) P† P‡
White blood cell count,  109/liter 9.9 (4.6–16.3) 16.8 (12.1–21.9) 12.2 (8–18.3) 0.0001 0.0001
Neutrophil count,  109/liter 5.4 (2.3–11.5) 11.9 (7.7–17.8) 6.8 (3.7–11.8) 0.0001 0.002
Hemoglobin, gm/liter 9.8 (8.3–11.1) 10.1 (9.1–11.2) 11.8 (10.8–12.7) 0.019 0.0001
Platelet count,  109/liter 144 (86–269) 498 (377–615) 340 (257–443) 0.0001 0.0001
Aspartate aminotransferase, units/liter 134 (58–338) 28 (20–39) 33 (25–44) 0.0001 0.0001
Alanine aminotransferase, units/liter 96 (37–234) 18 (11–34) 20 (13–32) 0.0001 0.0001
Lactate dehydrogenase, units/liter 1,203 (666–2,345) 438 (291–611) 507 (391–652) 0.0001 0.0001
Triglycerides, mg/dl 234 (151–318) 124 (91–142) 133 (100–192) 0.0001 0.0001
Albumin, gm/dl 3.1 (2.6–3.5) 3.5 (3–4) 3.8 (3.4–4.2) 0.0001 0.0001
Serum sodium, mmoles/liter 136 (132–138) 138 (135–140) 135 (133–138) 0.0001 0.99
Fibrinogen, mg/dl 267 (152–437) 559 (463–720) 411 (293–559) 0.0001 0.0001
D-dimer, ng/ml 2,996 (1,094–7,550) 2,050 (501–4,064) 417 (135–972) 0.004 0.0001
Ferritin, ng/ml 5,353 (1,500–13,040) 502 (158–1,627) 68 (33–133) 0.0001 0.0001
Erythrocyte sedimentation rate, mm/hour 48 (19–84) 78 (56–100) 40 (24–64) 0.0001 0.47
C-reactive protein, mg/dl 9.2 (3.5–17.7) 8.9 (4.8–15.3) 3.8 (0.8–10) 0.99 0.0001
* Values are the median (interquartile range). sJIA  systemic juvenile idiopathic arthritis; MAS  macrophage activation syndrome.
† Systemic juvenile idiopathic arthritis (JIA) with macrophage activation syndrome (MAS) versus systemic JIA without MAS, by Mann-Whitney
U test.
‡ Systemic JIA with MAS versus systemic infection, by Mann-Whitney U test.
Table 3. Frequency of fulfillment of individual items of the HLH-2004 guidelines in the patients with systemic JIA–associated MAS and control
patients*
Criterion
Systemic JIA with
MAS (n  362)
Systemic JIA without
MAS (n  404)
Systemic infection
(n  345) P† P‡
Fever 341/355 (96.1) 382/403 (94.8) 345 (100) 0.79 0.0006
Splenomegaly 201/347 (57.9) 95/399 (23.8) 23/344 (6.7) 0.0001 0.0001
Cytopenia (at least 2 of the 3 items) 64/299 (21.4) 2/264 (0.8) 9/337 (2.7) 0.0001 0.0001
Hemoglobin 90 gm/liter 120/335 (35.8) 84/389 (21.6) 21/343 (6.1) 0.0001 0.0001
Platelets 100  109/liter 112/338 (33.1) 5/387 (1.3) 14/344 (4.1) 0.0001 0.0001
Neutrophils 1.0  109/liter 25/297 (8.4) 2/267 (0.7) 8/340 (2.4) 0.0001 0.0017
Hypertriglyceridemia and/or hypofibrinogenemia 149/269 (62.8) 6/110 (5.5) 12/62 (19.4) 0.0001 0.0001
Triglycerides 265 mg/dl 113/278 (40.6) 5/137 (3.6) 12/96 (12.5) 0.0001 0.0001
Fibrinogen 1.5 gm/liter 73/294 (24.8) 2/213 (0.9) 1/138 (0) 0.0001 0.0001
Hemophagocytosis in bone marrow, spleen, or
lymph nodes
160/252 (63.5) – – – –
Low or absent NK cell activity – – – – –
Ferritin 500 ng/ml 277/308 (89.9) 136/270 (50.4) 7/209 (3.3) 0.0001 0.0001
Soluble CD25 2,400 units/ml – – – – –
* Values are the number of patients/total number with information available (%). HLH-2004  2004 diagnostic guidelines for hemophagocytic
lymphohistiocytosis; NK  natural killer.
† Systemic juvenile idiopathic arthritis (JIA) with macrophage activation syndrome (MAS) versus systemic JIA without MAS, by chi-square test.
‡ Systemic JIA with MAS versus systemic infection, by chi-square test.
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recorded in patients with MAS. CNS dysfunction and
hemorrhages occurred in approximately one-third and
one-fifth of the patients with MAS, respectively. The
most common CNS manifestations were, in order of
frequency, lethargy, seizures, irritability, confusion, head-
ache, mood changes, and coma (results not shown).
The sensitivity, specificity, and kappa values for
the adapted HLH-2004 guidelines and for the original
and modified preliminary MAS guidelines in the differ-
entiation of patients with MAS from control patients
are presented in Table 5. The 3/5-adapted HLH-2004
guidelines revealed a better tradeoff between sensitivity
and specificity and a higher kappa value than did the
4/5-adapted HLH-2004 guidelines in the discrimination
of patients with MAS from patients with systemic JIA
without MAS. The 4/5-adapted HLH-2004 guidelines
had maximum specificity, but poor sensitivity. The best
performance in distinguishing patients with MAS from
patients with systemic JIA without MAS was provided by
the original preliminary MAS guidelines, which showed
both strong sensitivity and strong specificity, as well as
the highest kappa value. The addition of the criterion of
hyperferritinemia, defined at any threshold, to the pre-
liminary MAS guidelines did not confer an appreciable
advantage in terms of sensitivity, and led to decreased
specificity and a decreased kappa value.
The 3/5-adapted HLH-2004 guidelines and the
preliminary MAS guidelines modified with the addition
of ferritin levels 500 ng/ml discriminated best between
patients with MAS and patients with systemic infection.
The 4/5-adapted HLH-2004 guidelines had maximum
specificity, but poor sensitivity, whereas the original
preliminary MAS guidelines were highly sensitive, but
poorly specific.
Table 6 shows the cutoff values, calculated through
the ROC curve analysis, as well as the sensitivity, spec-
ificity, AUC, and DOR of each individual laboratory
test for the differentiation between patients with MAS
and patients with systemic JIA without MAS. The best
tradeoff between sensitivity and specificity was provided
by the platelet count and the liver transaminase levels,
whereas ferritin levels showed the greatest sensitivity,
but only moderate specificity. The platelet count and
levels of liver transaminases, lactate dehydrogenase,
Table 4. Frequency of fulfillment of individual items of the preliminary MAS guidelines in the patients with systemic JIA–associated MAS and
control patients*
Criterion
Systemic JIA with
MAS (n  362)
Systemic JIA without
MAS (n  404)
Systemic infection
(n  345) P† P‡
Platelet count 262  109/liter 251/338 (74.3) 30/387 (7.8) 3/344 (0.9) 0.0001 0.0001
Aspartate aminotransferase 59 units/liter 244/327 (74.6) 29/367 (7.9) 49/324 (15.1) 0.0001 0.0001
White blood cell count 4.0  109/liter 72/240 (30) 2/389 (0.51) 19/341 (5.6) 0.0001 0.0001
Fibrinogen 2.5 gm/liter 140/294 (47.6) 9/213 (4.2) 24/138 (17.4) 0.0001 0.0001
Central nervous system dysfunction 122/349 (35) 7/400 (1.8) 34/344 (9.9) 0.0001 0.0001
Hemorrhages 71/348 (20.4) 5/402 (1.2) 22 (6.4) 0.0001 0.0001
Hepatomegaly 245/350 (70) 123/400 (30.8) 39/344 (11.3) 0.0001 0.0001
* Values are the number of patients/total number with information available (%).
† Systemic juvenile idiopathic arthritis (JIA) with macrophage activation syndrome (MAS) versus systemic JIA without MAS, by chi-square test.
‡ Systemic JIA with MAS versus systemic infection, by chi-square test.
Table 5. Sensitivity, specificity, and kappa values for the adapted HLH-2004 guidelines and the original and modified preliminary MAS guidelines
in the discrimination of patients with systemic JIA–associated MAS from patients in each control group*
Systemic JIA with MAS vs.
systemic JIA without MAS
Systemic JIA with MAS vs.
systemic infection
Sensitivity, % Specificity, % Kappa† Sensitivity, % Specificity, % Kappa†
Adapted HLH-2004 guidelines (3 of 5 criteria) 79 75 0.53 79 98 0.74
Adapted HLH-2004 guidelines (4 of 5 criteria) 35 100 0.36 35 100 0.36
Preliminary MAS guidelines 86 86 0.71 95 29 0.28
Preliminary MAS guidelines  ferritin 500 ng/ml 90 50 0.41 86 95 0.76
Preliminary MAS guidelines  ferritin 1,000 ng/ml 84 63 0.48 81 97 0.71
Preliminary MAS guidelines  ferritin 2,000 ng/ml 69 78 0.46 66 98 0.54
* HLH-2004  2004 diagnostic guidelines for hemophagocytic lymphohistiocytosis; MAS  macrophage activation syndrome; JIA  juvenile
idiopathic arthritis.
† Kappa values are Cohen’s kappa statistics calculated for concordance with the diagnosis made by the attending physician.
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triglycerides, fibrinogen, and ferritin were the sole lab-
oratory parameters that reached an AUC 0.80, and
these parameters, together with the neutrophil count,
had a DOR 10.
The laboratory test that discriminated best be-
tween patients with MAS and patients with systemic
infection was the ferritin level, followed by levels of
lactate dehydrogenase, levels of liver transaminases, the
platelet count, and levels of albumin (results available
from the corresponding author upon request). Notably,
4 patients with systemic infection were classified as
having MAS by a panel of experts in the web-based
consensus evaluations that preceded the consensus con-
ference in which the new classification criteria for MAS
in systemic JIA were developed (Ravelli A et al: unpub-
lished observations).
DISCUSSION
We compared the validity of the HLH-2004
guidelines with the validity of the preliminary MAS
guidelines as diagnostic tools for systemic JIA–
associated MAS by analyzing their potential to discrim-
inate between MAS and 2 conditions potentially con-
fusable with MAS, represented by active systemic JIA
without evidence of MAS and systemic infection. Both
the MAS sample and the control samples were com-
posed of large cohorts of patients recruited in large
referral hospitals located in 33 countries in 5 continents.
Of the 95 pediatric specialists who entered their pa-
tients’ data, 83 were rheumatologists and 12 were
hemato-oncologists. Notably, the hemato-oncologists
only had data from patients with MAS. Owing to its size
and sampling method, the study population is likely
representative of patients with MAS and control ill-
nesses seen in most tertiary care centers worldwide.
When we evaluated the ability of the guidelines
to differentiate MAS from systemic JIA without MAS,
we found that the preliminary MAS guidelines achieved
the best tradeoff between sensitivity and specificity and
the best concordance with the diagnosis made by the
attending physician. The statistical performance of the
3/5-adapted HLH-2004 guidelines was overall inferior to
that of the preliminary MAS guidelines, whereas the
4/5-adapted HLH-2004 guidelines revealed maximum
specificity, but poor sensitivity. The addition of ferritin
levels (at various thresholds) to the preliminary MAS
guidelines did not increase appreciably the specificity
and hampered the sensitivity. These results indicate that
the preliminary MAS guidelines in their original format
are best suited to diagnose MAS in patients with sys-
temic JIA.
The poorer sensitivity of the HLH-2004 guide-
lines was mainly explained by the low frequency of 2 of
the items, cytopenia (21.4%) and hypofibrinogenemia
(24.8%), in patients with MAS. Failure to meet these
criteria could be attributed to the uncommon occurrence
of a platelet count, neutrophil count, and fibrinogen
level below their respective thresholds of 100 109/liter,
1.0  109/liter, and 1.5 gm/liter. These findings may
imply that most cases of MAS were diagnosed before the
Table 6. Best thresholds, sensitivity, specificity, AUC, and DOR values obtained for each laboratory feature in the assessment of discrimination
between patients with systemic JIA–associated MAS and patients with systemic JIA without MAS*
Laboratory test
Best
threshold Sensitivity, % Specificity, % AUC (95% CI) DOR (95% CI)
White blood cell count,  109/liter 10.55 55 82 0.72 (0.69–0.76) 5.6 (4–7.8)
Neutrophil count,  109/liter 4.33 45 94 0.74 (0.701–078) 13.8 (7.8–24.4)
Hemoglobin, gm/liter 8.1 25 93 0.56 (0.52–0.6) 4.2 (2.6–6.6)
Platelet count,  109/liter 271 75 92 0.83 (0.86–0.9) 35.3 (22.7–54.9)
Aspartate aminotransferase, units/liter 60 74 93 0.88 (0.85–0.9) 36.4 (22.9–57.9)
Alanine aminotransferase, units/liter 39 74 83 0.84 (0.81–0.87) 14.4 (9.8–21)
Lactate dehydrogenase, units/liter 848 66 92 0.85 (0.81–0.88) 21.8 (13.2–36)
Triglycerides, mg/dl 160 72 85 0.82 (0.78–0.86) 14.7 (8.6–25.3)
Albumin, gm/dl 3.4 69 60 0.68 (0.64–0.72) 3.5 (2.4–4.9)
Serum sodium, mmoles/liter 135.9 51 74 0.66 (0.62–0.7) 2.9 (2–4.2)
Fibrinogen, mg/dl 397 71 88 0.84 (0.81–0.87) 18 (11.1–29.1)
D-dimer, ng/ml 5,900 32 88 0.62 (0.56–0.68) 3.6 (1.7–7.4)
Ferritin, ng/ml 1,040 84 66 0.82 (0.78–0.85) 10.2 (6.9–15.2)
Erythrocyte sedimentation rate, mm/hour 39 46 89 0.7 (0.67–0.74) 6.9 (4.6–10.4)
C-reactive protein, mg/dl 2.3 20 92 0.51 (0.47–0.54) 2.6 (1.6–4.2)
* AUC  area under the curve; DOR  diagnostic odds ratio; JIA  juvenile idiopathic arthritis; MAS  macrophage activation syndrome;
95% CI  95% confidence interval.
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drop in blood cell counts or drop in fibrinogen level
below the levels required by the HLH-2004 guidelines. It
is well known that patients with systemic JIA often have
increased white blood cell and platelet counts as well as
increased serum levels of fibrinogen as part of the
underlying inflammatory process. Thus, the occurrence
of a relative decline in these laboratory parameters,
rather than the absolute decrease required by the HLH-
2004 guidelines, may be more useful to make an early
diagnosis of MAS. When patients with systemic JIA
develop MAS, the degree of cytopenia and hypofibrino-
genemia seen in HLH may only be reached in the late
phase, when management may be more difficult. Re-
cently, the HLH-2004 guidelines were found to have low
sensitivity in the analysis of their ability to distinguish
systemic JIA–associated MAS from familial and virus-
associated HLH (23).
Although the stringency of the threshold levels
for cytopenia and hypofibrinogenemia may enhance the
specificity of the HLH-2004 guidelines, other items may
be poorly specific. The criterion of fever did not dis-
criminate between patients with MAS and control pa-
tients, since this feature was recorded in all or nearly
all patients in each sample. Unfortunately, we could
not obtain reliable information on the pattern of fever.
However, it is common knowledge that the onset of
MAS is often heralded by a shift from the high-spiking,
intermittent pattern typical of active systemic JIA to a
continuous, unremitting pattern (3–6). The criterion of
ferritin levels 500 ng/ml was present in 89.9% patients
with MAS, but also in 50.4% of patients with systemic
JIA without MAS, which suggests that such a threshold
level may not discriminate MAS from active systemic
JIA. It is well known that many patients with active
systemic JIA, in the absence of MAS, have ferritin levels
above that threshold (24). In the acute phase of MAS,
ferritin levels may peak to more than 5,000 ng/ml or
even 10,000 ng/ml. Thus, a ferritin threshold greater
than 500 ng/ml may be better suited to detect MAS in
systemic JIA.
Hemophagocytosis was identified in 63.5% of
MAS patients who had a bone marrow aspirate assessed
or a reticuloendothelial organ biopsy performed. Con-
sidering that in 30.4% of cases, confirmation by tissue
biopsy was not performed, the frequency of positive
histopathologic findings of hemophagocytosis in the
entire MAS sample was only 44.2%. Hemophagocytosis
is known to be frequently absent in both HLH and MAS,
particularly in their initial stages (25,26). Recently,
isolated hemophagocytosis in marrow core biopsy spec-
imens or aspirates was found to lack specificity for HLH
(12). Notably, the demonstration of hemophagocytosis is
not mandatory in either the HLH-2004 guidelines or the
preliminary MAS guidelines.
The good diagnostic performance of the prelim-
inary MAS guidelines was due to the strong ability of all
individual criteria to discriminate between MAS and
systemic JIA without MAS. However, among the labo-
ratory criteria assessed, the items decreased platelet
count and increased aspartate transaminase levels were
recorded much more frequently among patients with
MAS than were the items leukopenia and hypofibrino-
genemia. This finding suggests that the latter 2 items
may be less suitable for inclusion in a future revision of
the diagnostic guidelines. As expected, among the clin-
ical features observed, hepatomegaly was more common
than CNS dysfunction and hemorrhages. However, liver
enlargement was seen in 30.8% of patients with systemic
JIA without MAS. Thus, because mild hepatomegaly is a
frequent feature of active systemic JIA in the absence of
MAS, this criterion should probably be reformulated as
new-onset or worsening hepatomegaly. Surprisingly, the
addition of hyperferritinemia (at various thresholds) to
the preliminary MAS guidelines did not improve their
diagnostic performance, owing to the drop in specificity.
This phenomenon may be explained by the fact that
many patients with systemic JIA have high ferritin levels
in the absence of overt MAS or that the ferritin level
varies among patients with MAS.
The 3/5-adapted HLH-2004 guidelines and the
preliminary MAS guidelines modified with the addition
of ferritin levels500 ng/ml were the best discriminators
between MAS and systemic infection. The 4/5-adapted
HLH-2004 guidelines had maximum specificity, but poor
sensitivity, whereas the original preliminary MAS guide-
lines were highly sensitive, but poorly specific. In the
analysis of cutoff values for laboratory tests that pro-
vided the best discrimination between MAS and sys-
temic JIA without MAS, the parameters that reached an
AUC 0.80 were the platelet count, liver transaminase
levels, lactic dehydrogenase levels, triglyceride levels,
fibrinogen levels, and ferritin levels. These biomarkers
may be the best candidates for inclusion among labora-
tory criteria in a future revision of the MAS guidelines.
The cutoff for ferritin (1,040 ng/ml) revealed good
sensitivity, but modest specificity. This implies that the
criterion of ferritin levels alone may not be sufficient to
detect MAS, because some patients with active systemic
JIA without MAS may have a level above such a
threshold. However, the application of a higher thresh-
old may decrease sensitivity, that is, may lead to exclu-
sion of some instances of MAS.
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The laboratory parameters whose cutoff reached
an AUC 0.80 in the discrimination between MAS and
systemic infection were liver transaminase levels, lactate
dehydrogenase levels, and ferritin levels. It is noteworthy
that the discriminative potential of the ferritin level at a
cutoff of 394.1 ng/ml was very strong, with both sensi-
tivity and specificity being higher than 0.9 and the AUC
being 0.97. In addition, only the MAS group as a whole
demonstrated a ferritin level:ESR ratio of 80, a mea-
sure that has been suggested to distinguish MAS from
new-onset systemic JIA flare (27).
Our analysis should be interpreted in light of
some potential limitations. Patient data were collected
through the retrospective review of clinical charts. A
retrospective analysis is subject to the possibility of
missing data and possibly erroneous data. Owing to the
unavailability of data on bone marrow hemophagocyto-
sis in control patients and the lack of data on NK cell
activity and sCD25 levels in all patient samples, we could
only apply adapted versions of the HLH-2004 guide-
lines, based on the application of only 5 of the 8 original
criteria. Such an adaptation may have hampered the
diagnostic performance of these criteria. Notably, the
levels of sCD25 in the serum have been found to be
a potential marker for subclinical MAS in patients
with systemic JIA (6,28). However, NK cell activity or
sCD25 assessments are not routinely performed, nor are
they timely, in most pediatric rheumatology centers.
Although all of the study cases were defined as MAS
based on the clinician’s expert opinion, some pediatric
rheumatologists might have used the preliminary MAS
guidelines as reference. This phenomenon may partially
explain the better performance of these guidelines. We
should also recognize the caveat that diagnostic catego-
ries of systemic JIA with MAS and that without MAS
and febrile controls were determined by the reporting
physician, which could introduce a bias. Furthermore,
the accuracy of the diagnosis of MAS might have been
affected by the level of experience of the physicians who
participated in the study. However, the majority of the
patients were diagnosed in tertiary care referring cen-
ters. Notably, the characteristics of patients with MAS
enrolled by rheumatologists and those enrolled by
hemato-oncologists were comparable (Minoia F et al:
unpublished observations).
In conclusion, we found that the preliminary
MAS guidelines possessed the strongest ability to iden-
tify MAS in the setting of systemic JIA. The addition of
the item hyperferritinemia did not increase the sensitiv-
ity and specificity of the guidelines for MAS in systemic
JIA, but enhanced their capacity to differentiate MAS
from systemic infections. The diagnostic performance of
the HLH-2004 guidelines should be further scrutinized
in patient samples in which data on NK cell activity and
sCD25 levels are available. However, the limited avail-
ability and lack of timeliness of these assays likely
preclude their utility in identifying MAS in children with
systemic JIA worldwide.
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